olivLaw · US equity research
Lexeo Therapeutics, Inc. LXEO
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapies for cardiovascular diseases caused by genetic mutations, focused on cardiomyopathy in Friedreich ataxia. The company aims to become the first disease-modifying gene therapy for this condition, and its pivotal SUNRISE-FA 2 study was initiated in June 2026, with cash of $234.2 million that management says supports operations into 2028.
At the close of 04 Nov 2026, Lexeo Therapeutics, Inc. (LXEO) stock was 3.23 USD (+3.86% on the day), with market capitalisation 265.0 m USD, beta 2.15, 52-week range 2.63–10.63 USD. Latest reported quarter (Q2 2026): net income of -25.9 m USD, diluted EPS -0.30 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 51.3
- neutral
- Bollinger (20, 2)
- 2.56 – 3.34
- in the upper half of the band · %B 0.86 · band width 26.6%
- SMA 50 / 200
- 3.66 / 5.20
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.12 / -0.21
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −5.3% | −1.1% | −4.2 pp | — |
| 3 months | −27.4% | −0.5% | −27.0 pp | — |
| 6 months | −48.2% | +4.4% | −52.5 pp | — |
| Year to date | −67.5% | +12.3% | −79.8 pp | — |
| 1 year | −61.3% | +13.5% | −74.9 pp | −3.8% |
| 3 years | −67.9% | +76.4% | −144.3 pp | +18.6% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Research & development | 23.4 m | 18.4 m | 17.2 m | 14.7 m | 15.7 m | 16.2 m | 15.7 m | 19.0 m |
| Operating income | -31.5 m | -27.4 m | -33.8 m | -30.7 m | -21.6 m | -23.1 m | -22.3 m | -28.0 m |
| Depreciation & amortisation | 83.0 k ≈ | 75.0 k | 60.0 k | 62.0 k ≈ | 73.0 k ≈ | 73.0 k | 73.0 k | 74.0 k ≈ |
| Interest expense | 35.0 k | 30.0 k | 28.0 k | 25.0 k | 22.0 k | 20.0 k | 17.0 k | 14.0 k |
| Pre-tax income | -29.5 m | -26.0 m | -32.7 m | -26.1 m | -20.3 m | -20.6 m | -20.2 m | -25.9 m |
| Net income | -29.5 m | -25.9 m | -32.7 m | -26.1 m | -20.3 m | -20.9 m | -20.2 m | -25.9 m |
| Diluted EPS | -0.89 | -0.78 ≈ | -0.99 | -0.60 | -0.33 | -0.27 ≈ | -0.25 | -0.30 |
| Operating cash flow | -17.8 m ≈ | -28.3 m | -21.7 m | -27.2 m ≈ | -29.5 m ≈ | -20.1 m | -21.1 m | -17.6 m ≈ |
| Capex | 83.0 k ≈ | 0 | — | — | 289.0 k ≈ | 0 | 35.0 k | 7.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 654.0 k | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable |
| Net income | -59.3 m | -66.4 m | -98.3 m | -100.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -36.36 | -12.40 | -3.09 | -1.86 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | -9,063.8% | unavailable | unavailable | unavailable |
| Free cash flow | -55.2 m | -59.6 m | -81.6 m | -99.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 63.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 246.7 m USD
- Total assets
- 268.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 11.21x
- ROE
- -55.0%
- ROA
- -48.1%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 654.0 k | — | — | — | SEC (XBRL)· 11 Mar 2024verified |
| Research & development | 49.2 m | 53.1 m | 74.1 m | 63.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Operating income | -60.5 m | -68.5 m | -105.8 m | -109.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 120.0 k | 271.0 k | 304.0 k | 268.0 k | SEC (XBRL)· 30 Mar 2026verified |
| EBITDA | -60.4 m ≈ | -68.2 m ≈ | -105.5 m ≈ | -109.0 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Interest expense | 91.0 k | 205.0 k | 137.0 k | 95.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Pre-tax income | -59.3 m | -66.4 m | -98.4 m | -99.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | — | — | 0 | 0 | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -59.3 m | -66.4 m | -98.3 m | -100.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | -36.36 | -12.40 | -3.09 | -1.86 | SEC (XBRL)· 30 Mar 2026verified |
| Weighted average diluted shares | 1.6 m | 5.4 m | 31.8 m | 53.6 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 77.3 m | 121.5 m | 35.0 m | 63.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 80.0 m | 124.3 m | 126.1 m | 188.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 998.0 k | 1.1 m | 1.0 m | 1.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 97.1 m | 139.8 m | 146.9 m | 268.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 2.7 m | 3.8 m | 6.4 m | 4.9 m | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 14.3 m | 17.2 m | 22.8 m | 16.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 25.0 m | 26.3 m | 30.1 m | 22.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | -113.0 m † | 113.5 m † | 116.8 m † | 246.7 m † | SEC (XBRL)· 30 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -54.6 m | -59.5 m | -81.2 m | -98.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 672.0 k | 115.0 k | 481.0 k | 397.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -55.2 m ≈ | -59.6 m ≈ | -81.6 m ≈ | -99.0 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -901.0 k | -165.0 k | -94.1 m | -90.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 189.0 k | 103.8 m | 88.8 m | 216.8 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 265.0 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -1,303.0x | 0 (on a fixed band) | 33% |
| Current ratio · Balance sheet | 13.9x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -33.5% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Lexeo Therapeutics, Inc. (LXEO). Latest full fiscal year: 2022; data up to 2026-06-30.
Figures computed from the financial statements: revenue 654.0 k USD in 2022; ROE -46.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 13.9x
What contradicts it
- Interest coverage: -1,303.0x
- FCF yield: -33.5%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| MESOMesoblast Limited | 18.5 bn | — | -19.0% | -593.9% | +191.4% | −17% / +425% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| TWSTTwist Bioscience Corporation | 8.9 bn | — | -29.6% | -31.7% | +20.3% | +345% / +493% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +51% / unavailable |
| TARSTarsus Pharmaceuticals, Inc. | 3.4 bn | — | -319.8% | -102.9% | +146.7% | −14% / +318% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| VCELVericel Corporation | 2.3 bn | 107.7 | 7.2% | 7.9% | +16.5% | +13% / +28% |
| ADMAAdma Biologics, Inc. | 2.3 bn | 13.6 | 41.9% | 35.1% | +19.6% | −45% / +183% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -37.4% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -21.8% | -61.0% | −7.6% | +83% / +24% |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| SRZNSurrozen, Inc. | 372.0 m | — | — | -2,885.3% | −67.4% | +91% / +340% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| LXEOLexeo Therapeutics, Inc. | 265.0 m | — | -46.8% | — | unavailable | −61% / −68% |
1- and 3-year price returns: for LXEO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapies for cardiovascular diseases caused by genetic mutations, focused on cardiomyopathy in Friedreich ataxia. The company aims to become the first disease-modifying gene therapy for this condition, and its pivotal SUNRISE-FA 2 study was initiated in June 2026, with cash of $234.2 million that management says supports operations into 2028 2.
SWOT
Strengths
- A diverse candidate portfolio with significant FDA designations, including Breakthrough Therapy, RMAT and Orphan Drug 13.
- A proprietary baculovirus/Sf9 manufacturing platform that is potentially scalable 1.
- Interim clinical data showing cardiac and functional improvements in LX2006-treated patients 1.
Weaknesses
Opportunities
- Could become the first disease-modifying gene therapy for Friedreich ataxia cardiomyopathy if the pivotal study confirms benefit 3.
- Expansion into more prevalent genetic cardiomyopathies could increase the commercial potential of the platform 1.
- Development partnerships for the APOE4-associated Alzheimer's programs could bring additional funding 1.
Risks
- Dependence on clinical trialshigh
Development depends on pivotal study results, and interim data may change as additional patient data become available 1.
- Need for additional fundinghigh
The company will need substantial capital and could resort to dilution if financing is not available on acceptable terms 12.
- Regulatory uncertaintyhigh
Approval depends on the FDA and other authorities, and the process may be lengthy and unpredictable 1.
- Manufacturing and third-party suppliersmedium
The company relies on third-party suppliers and manufacturing partners, and capacity or quality problems could delay projects 1.
- Therapy safetymedium
Adverse events have been reported, including one possibly treatment-related case, and new safety issues could limit development 2.
Investment thesis
What would need to be true (bull case)
- If the SUNRISE-FA 2 study confirms clinical benefit, LX2006 could become a treatment option for a condition with no approved cardiac therapy 13.
- Breakthrough Therapy and RMAT designations may accelerate the regulatory process for several programs 13.
- The AAVrh10 vector platform and manufacturing process could support expansion to larger patient populations if clinical data remain favorable 1.
What would break the thesis
- The company has no product revenue and continues to incur substantial losses, making dependence on external financing a major weakness 12.
- Clinical data are still preliminary and based on small samples, and pivotal study results could differ from interim findings 1.
- Accelerated approval depends on FDA acceptance of confirmatory evidence, which is still under discussion 2.
What to watch
- Topline results from SUNRISE-FA 22H 2027
- 12-month data update for high-dose LX2020 participantsQ4 2026
- BLA submission for LX2006 under accelerated approval1H 2028
- Cash position and runway into 20282028
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on treating cardiovascular diseases by addressing their genetic causes 1. Its portfolio includes LX2006 for Friedreich ataxia cardiomyopathy, LX2020 for PKP2 arrhythmogenic cardiomyopathy, and preclinical programs such as LX2021 and LX2022 1. The company holds exclusive worldwide development and commercialization rights to all its candidates 1.
The technology is based on the AAVrh10 vector, chosen for high transduction efficiency in myocardial cells and a more favorable cardiac-to-liver biodistribution than other AAV serotypes 1. The manufacturing process uses a baculovirus/Sf9 system designed for larger-scale production at cost-of-goods similar to biologics 1.
The company has no approved products and has never generated revenue from product sales 1. It has funded operations through equity and convertible securities, and in July 2026 sold common stock under its ATM program 2.
Segments
LX2006 - Friedreich ataxia cardiomyopathy
LX2006 is the most advanced candidate, being evaluated in the SUNRISE-FA study and a Cornell investigator-initiated trial 1. It has received Breakthrough Therapy and RMAT designations from the FDA 1. The pivotal SUNRISE-FA 2 study was initiated in June 2026, with topline data expected in the second half of 2027 3.
Market context
The target market consists of genetically defined populations with few or no approved treatments addressing the genetic cause of disease 1. Friedreich ataxia affects approximately 5,000 patients in the United States, and PKP2 mutations are estimated to affect approximately 60,000 patients in the United States 1. The only approved Friedreich ataxia treatment targets the neurologic component rather than the cardiac one 1.
Market size depends on clinical success and regulatory approvals, which remain uncertain, and the timing of commercialization could depend on pivotal study results and FDA discussions 2.
Trends
- Accelerated regulatory pathwaytailwind
The FDA has opened the door to a BLA for accelerated approval of LX2006, which could shorten the time to submission if the data are sufficient 1. The confirmatory evidence strategy is still under FDA discussion 2.
- FDA designations for advanced therapiestailwind
Breakthrough Therapy, RMAT and CDRP designations could facilitate FDA interaction and faster development, although they do not guarantee approval 13.
- Complexity of gene therapy manufacturingheadwind
Gene therapies are difficult to manufacture at scale, and manufacturing problems could delay development or commercialization 1.
- Access to capitalmixed
The company relies on external financing, and continued cash burn could substantially change the funding outlook 2.
Competitive position
Direct competition for Friedreich ataxia cardiomyopathy is limited, since no approved treatments address the cardiac component 1. Indirect competition includes therapies targeting the neurologic aspects of the disease or other genetic approaches in cardiology 1.
In PKP2-mutation ACM and other genetic cardiomyopathies, competition may come from other gene therapy companies and existing symptomatic treatments, and relative positioning will depend on future clinical data 1.
- Biogen (Skyclarys, approved for Friedreich ataxia)BIIB
The approved treatment named in the source targets the neurologic component of the disease, not the cardiac one 1.
- Other cardiac gene therapy companies
The source does not name specific competitors; competition in this field is mentioned only in general terms.
- Academic partner centers (Weill Cornell Medicine)
Academic collaborations support research and investigator-initiated studies and are not direct competitors 1.
- Existing symptomatic therapies and standards of care
Existing treatments for arrhythmias and heart failure may compete for clinician and patient attention.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Sept 2026Acquisition or disposition of assets · Item 3.02 · Financial statements and exhibits
- Current report22 Sept 2026Material agreement · Other events · Financial statements and exhibits
- Quarterly report12 Aug 2026
- Current report12 Aug 2026Results of operations · Other events · Financial statements and exhibits
- Current report29 Jun 2026Shareholder vote
- Current report15 Jun 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report11 May 2026
- Current report11 May 2026Results of operations · Other events · Financial statements and exhibits
- Proxy statement30 Apr 2026
- Current report30 Apr 2026Departure or appointment of officers
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Lexeo Therapeutics, Inc. · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Lexeo Therapeutics, Inc. · 12 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Lexeo Therapeutics, Inc. · 12 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.